ArticleJournal of surgical case reports2026
Deceased donor interposition graft repair of superior mesenteric artery injury during cytoreductive nephrectomy for metastatic renal cell carcinoma.
Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iatrogenic injury to the superior mesenteric artery (SMA) represents a rare but serious complication of nephrectomy, associated with significant morbidity and mortality. Repair can be technically challenging. We describe the case of a 71-year-old patient who had an SMA injury during an open nephrectomy for a large carcinoma. Her SMA was reconstructed successfully using a deceased-donor iliac artery interposition graft. Due to her high-risk pathology and progressive disease early in the post-operative period, she was commenced on lenvatinib and pembrolizumab. Despite the vascular allograft, immunosuppression was not used due to concerns about an interaction with immunotherapy. To date, she has had an excellent treatment response with a significant reduction in metastatic burden without the development of rejection of the vascular allograft, despite no immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.